With the UK’s default to leave the EU without a deal, there are a number of steps businesses in the life sciences sector should take to prepare. Many companies in the sector are faced with simultaneously navigating an increasingly complex regulatory environment while trying to mitigate as much as possible the significant impact of Brexit – including the effects of weak drug development pipelines, access to talent, supply chain disruption and potentially reduced research and development (R&D) funding.
Only logged in customers who have purchased this product may leave a review.
You may also like
Organizations- and their Technology and Cyber Risk Management (TCRM) functions- are being buffeted by changing dynamics bringing ever-increasing risks: mounting regulatory pressures, innovative new technology, an evolving workforce in need of new skills, and organizational shifts that create cyber and information security challenges.
Four Key steps to fuel a proactive tech and cyber risk function$0.00 KPMG
Digital Transformation in the Finance Function
Digital transformation in the finance function$0.00 Oliver Wyman
In this year’s State of Financial Services report we examine the potential for the industry to start again. We explore the power of new – areas in the industry where new technology and businesses are having a proven impact. We show how existing firms can deploy a greenfield approach to deliver new growth and to accelerate transformation of the existing business.
The State of the Financial Services Industry 2019: Time to Start againRated 4.00 out of 5$0.00 Oliver Wyman
Trouble with Conavigo
Want to refine your results?
Help with Sourcing
Need help with your Sourcing?